

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**SkyNet Group Limited**  
**航空互聯集團有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 8176)**

**VOLUNTARY ANNOUNCEMENT**

**STRATEGIC JOINT DEVELOPMENT FRAMEWORK AGREEMENT WITH  
蘇州景昱醫療器械有限公司 (SUZHOU JINGYU MEDICAL DEVICE CO., LTD\*)**

This is a voluntary announcement made by SkyNet Group Limited (the “**Company**”).

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that, on 19 April 2017, 深圳市安澤智能工程有限公司 (Shenzhen Anzer Intelligence Engineering Company Limited\* or “**Anzer**”), a 99% owned subsidiary of the Company, entered into a strategic joint development framework agreement (the “**Joint Development Agreement**”) with 蘇州景昱醫療器械有限公司 (Suzhou Jingyu Medical Device Co., Ltd \* or “**Suzhou Jingyu**”). Pursuant to the Joint Development Agreement, the parties agreed to jointly research and develop surgery assisting robots for the implantation of deep brain stimulation system with nuclear magnetic resonance apparatus (the “**Platform**”).

Suzhou Jingyu is a medical device company mainly focused on the design, development, and distribution of neuromodulator devices. The research & development team of Suzhou Jingyu was established in July 2009. The team has already obtained 122 patents till now, including two patents in the United States of America. The team has successively completed the design and testing of deep brain stimulation (“**DBS**”) system, DBS performance validation, DBS animal experiments based on Rhesus and clinical trial at a number of centers in China. In 2014, Suzhou Jingyu DBS entered the Innovation Special Project Approval Process of Chinese Food and Drug Administration (“**CFDA**”). In June 2015, Suzhou Jingyu DBS obtained the registration of CFDA.

Under the Joint Development Agreement, Suzhou Jingyu will specify the requirement of the Platform for the implantation of deep brain stimulation system. Anzer will develop the Platform based on the requirement given by Suzhou Jingyu. The Joint Development Agreement is mutually exclusive and the parties will jointly own any intellectual properties derived from the joint development.

The Joint Development Agreement has a term of three (3) years from date of signing. In the event that the joint development is not materialized due to unforeseeable events or any party fails to or delay in meeting terms specified in the Joint Development Agreement, either party can terminate the Joint Development Agreement by giving written notice to the other party. The Company will make further announcement in respect of the Joint Development Agreement in due course in accordance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) if and when required.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**SkyNet Group Limited**  
**Cai Zhaoyang**

*Executive Director, Chairman and Chief Executive Officer*

Hong Kong, 19 April 2017

*As at the date of this announcement, the Board comprises six executive Directors, namely Mr. Cai Zhaoyang, Mr. Chan Kin Wah, Billy, Mr. Lee Chan Wah, Mr. Zhang Chong, Mr. Zhang Chongdi and Dr. Andrew Goldenberg; and three independent non-executive Directors, namely Mr. Tam B Ray, Billy, Mr. Chu Kin Wang, Peleus and Mr. Tse Joseph.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the website of the Growth Enterprise Market at <http://www.hkgem.com> for at least 7 days from the date of its posting and be posted on the website of the Company at <http://www.skynetgroup.com.hk>.*

\* *For identification purposes only*